J B Chemicals & Pharmaceuticals Ltd Q4 FY25 Earnings Analysis

Published 18 Jul 2026 | Market Cap: ₹34.4K Cr

Price

2,409

Market Cap

₹34.4K Cr

P/E Ratio

47.1

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were J B Chemicals & Pharmaceuticals Ltd Q4 FY25 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is J B Chemicals & Pharmaceuticals Ltd share price analysis?

J B Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹34,366. Investors should review the full earnings analysis for detailed insights.

Is J B Chemicals & Pharmaceuticals Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Acutaas Chemicals Ltd (Q4 FY25)

    Acutaas Chemicals Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹26,877, P/E 6

  • Cohance Lifesciences Ltd (Q4 FY25)

    Cohance Lifesciences Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹16,429, P/

  • Advanced Enzyme Technologies Ltd (Q4 FY25)

    Advanced Enzyme Technologies Ltd Q4 FY25 quarterly results analysis. - The management aspires to achieve at least double-digit growth but is cautious due to rec

  • Torrent Pharmaceuticals Ltd (Q4 FY25)

    Torrent Pharmaceuticals Ltd Q4 FY25 quarterly results analysis. - India business continues to outperform market growth with 12-13% revenue growth YTD; focus on